
|Articles|April 15, 2003
Anti-VEGF treatment shows promise in preliminary trials
Boston-Multiple intravitreal injections of rhuFab V2 (Genentech Inc., San Francisco) are well-tolerated and appear to have favorable biologic activity for the treatment of exudative age-related macular degeneration (AMD), said Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston and the Center for Eye Research, principal investigator for that trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Seeing the difference: Multimodal imaging for AMD and GA
2
Strategic approaches optimize teaching and learning in the clinic
3
Dompé enrolls first patients in phase 3 study of isocyclosporin for treatment of atopic keratoconjunctivitis
4
Spotlight on women's health: Understanding thyroid eye disease
5








































